DexCom, Inc. $DXCM Shares Purchased by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC increased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 13.7% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 8,713 shares of the medical device company’s stock after purchasing an additional 1,049 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in DexCom were worth $761,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DXCM. Brighton Jones LLC raised its holdings in DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after purchasing an additional 11,946 shares during the last quarter. State of Alaska Department of Revenue raised its holdings in DexCom by 2.7% during the first quarter. State of Alaska Department of Revenue now owns 45,740 shares of the medical device company’s stock worth $3,123,000 after purchasing an additional 1,205 shares during the last quarter. GAM Holding AG raised its holdings in DexCom by 17.3% during the first quarter. GAM Holding AG now owns 11,177 shares of the medical device company’s stock worth $763,000 after purchasing an additional 1,647 shares during the last quarter. Praxis Investment Management Inc. raised its holdings in DexCom by 3.3% during the first quarter. Praxis Investment Management Inc. now owns 11,910 shares of the medical device company’s stock worth $813,000 after purchasing an additional 380 shares during the last quarter. Finally, First American Bank raised its holdings in DexCom by 2.8% during the first quarter. First American Bank now owns 26,988 shares of the medical device company’s stock worth $1,843,000 after purchasing an additional 725 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Kyle Malady sold 667 shares of DexCom stock in a transaction on Friday, September 5th. The stock was sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the sale, the director owned 22,667 shares of the company’s stock, valued at $1,832,853.62. The trade was a 2.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the sale, the executive vice president directly owned 105,223 shares of the company’s stock, valued at approximately $8,417,840. This represents a 1.37% decrease in their position. The disclosure for this sale can be found here. Insiders sold 6,849 shares of company stock worth $564,733 in the last three months. Company insiders own 0.32% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $66.60 on Friday. The company has a market cap of $26.12 billion, a P/E ratio of 46.25, a P/E/G ratio of 1.40 and a beta of 1.47. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $93.25. The business has a fifty day simple moving average of $73.35 and a 200-day simple moving average of $77.58.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business’s revenue for the quarter was up 15.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. Equities research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analysts Forecast Growth

DXCM has been the subject of several research reports. Truist Financial reduced their price objective on DexCom from $102.00 to $94.00 and set a “buy” rating for the company in a report on Wednesday. The Goldman Sachs Group dropped their price target on DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a research report on Wednesday, October 1st. Wall Street Zen downgraded DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 10th. Mizuho raised their price target on DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 16th. Finally, Citigroup dropped their price target on DexCom from $105.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, October 7th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $97.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.